Topic: Mental Health Research Network
Conditions
Interventions
Those allocated to the experimental treatment will receive CBSPp as described in the manual in addition to treatment as usual (TAU). Treatment will take place over 12 weeks. Participants will be seen
Sponsors
University of Manchester (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) diagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder or psychotic disorder not otherwise specified (NOS) 2. Have had previous suicide attempts or current suicidal ideation 3. Are not currently acutely suicidal or considered a danger to themselves or others 4. Are receiving appropriate anti-psychotic medication 5. Are under the care of an appropriate clinical team and have contact with mental health service 6. Males and females aged between 18 and 65 years
Exclusion criteria
Exclusion criteria: Not providing informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Suicidal behaviour, measured at 4 months and 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Measured at baseline, 4 months and 6 months: 1. Beck Anxiety Inventory (BAI) to assess level of anxiety 2. Beck Hopelessness Scale 3. Calagary Depression Scale for Schizophrenia 4. Global assessment of functioning (DSM-IV) to assess overall functioning 5. Positive And Negative Symptoms Scale (PANSS) to assess severity of symptoms 6. Psychotic Symptom Rating Scales (PSYRATS) to assess control over symptoms 7. Questionnaire about the Process of Recovery (QPR) 8. Self Esteem Rating Scale 9. The Subjective Experiences of Psychotic Symptoms Scale (SEPSS) | — |
Countries
United Kingdom
Outcome results
None listed